Suppr超能文献

JNK 在 Trp53 依赖性乳腺癌小鼠模型中的作用。

Role of JNK in a Trp53-dependent mouse model of breast cancer.

机构信息

Howard Hughes Medical Institute, Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.

出版信息

PLoS One. 2010 Aug 30;5(8):e12469. doi: 10.1371/journal.pone.0012469.

Abstract

The cJun NH2-terminal kinase (JNK) signal transduction pathway has been implicated in mammary carcinogenesis. To test the role of JNK, we examined the effect of ablation of the Jnk1 and Jnk2 genes in a Trp53-dependent model of breast cancer using BALB/c mice. We detected no defects in mammary gland development in virgin mice or during lactation and involution in control studies of Jnk1(-/-) and Jnk2(-/-) mice. In a Trp53(-/+) genetic background, mammary carcinomas were detected in 43% of control mice, 70% of Jnk1(-/-) mice, and 53% of Jnk2(-/-) mice. These data indicate that JNK1 and JNK2 are not essential for mammary carcinoma development in the Trp53(-/+) BALB/c model of breast cancer. In contrast, this analysis suggests that JNK may partially contribute to tumor suppression. This conclusion is consistent with the finding that tumor-free survival of JNK-deficient Trp53(-/+) mice was significantly reduced compared with control Trp53(-/+) mice. We conclude that JNK1 and JNK2 can act as suppressors of mammary tumor development.

摘要

cJun NH2-末端激酶(JNK)信号转导通路与乳腺癌的发生有关。为了测试 JNK 的作用,我们使用 BALB/c 小鼠,在依赖 Trp53 的乳腺癌模型中,检测了 Jnk1 和 Jnk2 基因缺失的影响。在对照研究中,我们没有发现 Jnk1(-/-)和 Jnk2(-/-)小鼠在处女期或哺乳期及退化期乳腺发育有缺陷。在 Trp53(-/+)遗传背景下,43%的对照小鼠、70%的 Jnk1(-/-)小鼠和 53%的 Jnk2(-/-)小鼠发生了乳腺癌。这些数据表明,JNK1 和 JNK2 对于 Trp53(-/+)BALB/c 乳腺癌模型中的乳腺肿瘤发展并非必需。相比之下,这一分析表明 JNK 可能部分有助于肿瘤抑制。这一结论与 JNK 缺陷型 Trp53(-/+)小鼠的无肿瘤生存时间明显短于对照 Trp53(-/+)小鼠的发现一致。我们得出结论,JNK1 和 JNK2 可以作为乳腺肿瘤发展的抑制因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f86/2930003/9e0c4b18794e/pone.0012469.g001.jpg

相似文献

1
Role of JNK in a Trp53-dependent mouse model of breast cancer.
PLoS One. 2010 Aug 30;5(8):e12469. doi: 10.1371/journal.pone.0012469.
2
Role of JNK in mammary gland development and breast cancer.
Cancer Res. 2012 Jan 15;72(2):472-81. doi: 10.1158/0008-5472.CAN-11-1628. Epub 2011 Nov 29.
3
Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death.
Mol Immunol. 2009 Dec;47(2-3):310-7. doi: 10.1016/j.molimm.2009.09.016. Epub 2009 Oct 27.
4
Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice.
Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1122-31. doi: 10.1161/ATVBAHA.116.307580. Epub 2016 Apr 21.
5
Differential transmission of MEKK1 morphogenetic signals by JNK1 and JNK2.
Development. 2008 Jan;135(1):23-32. doi: 10.1242/dev.007120. Epub 2007 Nov 21.
6
c-Jun N-terminal kinase 1 phosphorylates Myt1 to prevent UVA-induced skin cancer.
Mol Cell Biol. 2009 Apr;29(8):2168-80. doi: 10.1128/MCB.01508-08. Epub 2009 Feb 9.
9
JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.
Am J Pathol. 2011 Oct;179(4):1884-93. doi: 10.1016/j.ajpath.2011.06.019. Epub 2011 Aug 11.
10
c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.
Diabetologia. 2008 Dec;51(12):2271-80. doi: 10.1007/s00125-008-1169-7. Epub 2008 Oct 14.

引用本文的文献

1
Pathophysiological Significance of WDR62 and JNK Signaling in Human Diseases.
Front Cell Dev Biol. 2021 Apr 16;9:640753. doi: 10.3389/fcell.2021.640753. eCollection 2021.
2
Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide.
Cancers (Basel). 2019 Jun 20;11(6):858. doi: 10.3390/cancers11060858.
3
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.
Nat Commun. 2019 May 13;10(1):2139. doi: 10.1038/s41467-019-10138-8.
4
JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells.
ACS Chem Biol. 2019 Jul 19;14(7):1426-1435. doi: 10.1021/acschembio.9b00083. Epub 2019 May 17.
5
The ERK and JNK pathways in the regulation of metabolic reprogramming.
Oncogene. 2019 Mar;38(13):2223-2240. doi: 10.1038/s41388-018-0582-8. Epub 2018 Nov 28.
7
The cJUN NH-terminal kinase (JNK) pathway contributes to mouse mammary gland remodeling during involution.
Cell Death Differ. 2018 Sep;25(9):1702-1715. doi: 10.1038/s41418-018-0081-z. Epub 2018 Mar 6.
9
JNK pathway inhibition enhances chemotherapeutic sensitivity to Adriamycin in nasopharyngeal carcinoma cells.
Oncol Lett. 2017 Aug;14(2):1790-1794. doi: 10.3892/ol.2017.6349. Epub 2017 Jun 8.
10
Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Exp Hematol. 2017 Sep;53:16-25. doi: 10.1016/j.exphem.2017.04.009. Epub 2017 May 4.

本文引用的文献

2
Induction of hepatitis by JNK-mediated expression of TNF-alpha.
Cell. 2009 Jan 23;136(2):249-60. doi: 10.1016/j.cell.2008.11.017.
3
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation.
J Clin Invest. 2008 Dec;118(12):3943-53. doi: 10.1172/JCI37156. Epub 2008 Nov 6.
4
The genomic landscapes of human breast and colorectal cancers.
Science. 2007 Nov 16;318(5853):1108-13. doi: 10.1126/science.1145720. Epub 2007 Oct 11.
5
Suppression of p53-dependent senescence by the JNK signal transduction pathway.
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15759-64. doi: 10.1073/pnas.0707782104. Epub 2007 Sep 24.
6
Role of mitogen-activated protein kinase kinase 4 in cancer.
Oncogene. 2007 May 14;26(22):3172-84. doi: 10.1038/sj.onc.1210410.
7
The JNK signal transduction pathway.
Curr Opin Cell Biol. 2007 Apr;19(2):142-9. doi: 10.1016/j.ceb.2007.02.001. Epub 2007 Feb 15.
8
c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells.
Cancer Res. 2006 Oct 15;66(20):10024-31. doi: 10.1158/0008-5472.CAN-06-0136.
9
JNK2 is a positive regulator of the cJun transcription factor.
Mol Cell. 2006 Sep 15;23(6):899-911. doi: 10.1016/j.molcel.2006.07.028.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验